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Background: Mutations of the lamin A/C gene have been associated with several diseases such as Emery-Dreifuss
muscular dystrophy, dilated cardiomyopathy and Charcot-Marie-Tooth disease, referred to as laminopathies. Only
one report of spinal muscular atrophy and cardiomyopathy phenotype with lamin A/C gene mutations has been
published. The concept that lamin A/C gene mutations cause spinal muscular atrophy has not been established.
Case presentation: We report a man aged 65 years who presented with amyotrophy of lower limbs, arrhythmia
and cardiac hypofunction. He showed gait disturbance since childhood, and his family showed similar symptoms.
Neurological and electrophysiological findings suggested spinal muscular atrophy type 3. Gene analysis of lamin
A/C gene showed a novel nonsense mutation p.Q353X (c.1057C > T). Further investigations revealed that he and
his family members had cardiac diseases including atrioventricular block.
Conclusions: We report the first Japanese case of spinal muscular atrophy phenotype associated with lamin A/C
mutation. When a patient presents a spinal muscular atrophy phenotype and unexplained cardiac disease,
especially when the family history is positive, gene analysis of lamin A/C gene should be considered.
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Spinal muscular atrophy (SMA) is classified as a lower
motor neuron disease, and is caused by degeneration of
neurons in the anterior horn of the spinal cord. SMA is
clinically classified into five subtypes based on onset age
and progression [1,2]. In Japan, most of the patients with
SMA types 1 and 2 have deletions or mutations of the
survival motor neuron gene (SMN1), while only one-half
of the patients with SMA type 3 have SMN1 deletions or
mutations [3], and other responsible genes are rarely
identified.
Since Sterz et al. [4] reported SMA type 3 with dis-
turbed cardiac rhythm in two brothers, only a few re-
ports described cardiac involvement in SMA. Most of
the reported cases demonstrated atrial arrhythmia and/
or a variable degree of atrioventricular block. Addition-
ally, some cases had cardiac dysfunction with ventricular* Correspondence: shimoha@sapmed.ac.jp
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unless otherwise stated.and atrial dilatations commonly seen in dilated cardio-
myopathy (DCM) [5]. The genetic factor underlying this
combined phenotype had remained unknown until
Rudnik-Schöneborn et al. [6] reported lamin A/C gene
(LMNA) mutations in families with adult-onset SMA
and cardiac disease.
We report the first Japanese case of SMA with cardiac
diseases associated with LMNA, and a novel nonsense
mutation p.Q353X (c.1057C > T).
Case presentation
A 65 year-old Japanese man attended for the first time
to Sapporo Medical University Hospital, and was admit-
ted because of gait disturbance and amyotrophy of lower
limbs. No perinatal abnormalities were observed, except
that he had been enable to walk until three years old. He
was clumsy in running since childhood and walking be-
came gradually more difficult with age. He had attended
to other neurological hospital in his 40s having given no
reasonable diagnosis, stopped seeing doctors. He began
to use a walker two years before admission. He had al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Medical Research Council Scale and needle
electromyograms of the patient
MRC nEMG
Lt Rt Lt
Neck extension 5 NE
Neck flexion 4 NE
Dorsal flexion 4
(Th10 paraspinal muscle) Chronic neurogenic change
Deltoid 5 5 NE
Biceps 4 4 Chronic neurogenic change
Triceps 5 5 NE
Wrist extension 3 5 NE
Wrist flexion 5 5 NE
Iliopsoas 4 4 NE
Gluteus medius 3 3 NE
Quadriceps 3 3 Chronic neurogenic change
Hamstrings 3 3 NE
Tibialis anterior 3 4 Chronic neurogenic change
Gastrocnemius 2 3 Chronic neurogenic change
MRC: Medical Research Council Scale, nEMG: needle electromyograms, NE:
not examined.
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complete atrioventricular block at 45 years, after which a
pacemaker was implanted at other hospital. He had
hypertension since the age of 57, and had two attacks of
cerebral embolism in the last decade.
The pedigree of his family is shown in Figure 1. His
mother (I-3), two uncles (I-6, 8) and sister (II-2) had gait
disturbance, and his sister (II-2) also had a pacemaker
implanted due to atrioventricular block. However, no de-
tailed information on disease onset and progression was
available in their medical records. His sister also had gait
disturbance since childhood and atrioventricular block
was detected in early adulthood. She had more severe
muscle weakness than the patient, and was unable to get
up by herself. She could not come to our hospital be-
cause of her physical condition, and rejected to get a
genetic analysis. His mother and sister had hypertension
and ischemic stroke. His children were in their 30’s and
remained healthy with no gait disturbance and cardiac
disease. Our investigation found no consanguineous
marriage.
On admission, his heart rate was 60 rpm (pacemaker
rhythm), and blood pressure was 119/75 mmHg while
on antihypertensive drugs. Whereas transthoracic echo-
cardiography showed diffuse cardiac hypofunction with
ejection fraction 42%, no ventricular and atrial dilata-
tions were observed. According to his medical record,
his ejection fraction was 62% in his 50’s and had deterio-
rated gradually.
A neurological examination revealed significant
muscle weakness in lower limbs with pes cavus. The ex-
tent of muscle weakness was the same in the proximal
and distal parts of lower limbs (Table 1). Muscle weak-
ness in upper limbs and swallowing impairment were
mild (Table 1). Mild joint contracture was observed in
his right knee joint. Muscle weakness was more promin-
ent on the left side because of ischemic stroke (Table 1).
Fasciculation was observed in both legs. His tendon re-
flexes were absent. There were no abnormalities in sen-





Figure 1 Pedigree of the patient’s family. Arrow indicates the
patient as II-3. The genetic analysis was limited to the proband, as
we could not get a permission from other family members.function showed mild cognitive impairment, with Mini-
Mental State Examination score of 23/30 and Frontal
Assessment Battery score of 12/18.
Examinations of blood and cerebrospinal fluid showed
no remarkable abnormalities, and creatine kinase was
slightly high (179 IU/L: normal value 45–160 IU/L). The
patient refused a muscle biopsy. A brain computed tom-
ography scan revealed multiple old cerebral infractions,
but hippocampal atrophy was not indicated.
A motor conduction study of the tibial nerve showed
low amplitude compound muscle action potential with
no decrease in conduction velocity. F wave studies
showed repeater F waves in median and tibial nerves,
with low persistence. However, sensory nerve conduc-
tion studies of median, ulnar and sural nerves were nor-
mal. Needle electromyogram showed chronic neurogenic
changes especially in the lower limbs (Table 1, Figure 2).
These results strongly suggested degeneration of lower
motor neurons.
With a presumptive diagnosis of SMA type 3, we con-
ducted gene analysis. Exon 7 and 8 deletions of SMN1
were not found. Early-onset muscular atrophy combined
with cardiomyopathy made us to consider the possibility
of inherited Charcot-Marie-Tooth disease (CMT) as a
differential diagnosis. Some familial cases of SMA phe-
notypes with cardiac involvement were reported in some
parts of Japan [5], and, within the responsible genes of
CMT, LMNA mutations were reported to cause SMA
phenotype with cardiac involvement in Germany [6]. For









Figure 2 Needle electromyograms of lower limbs. Needle
electromyograms show chronic neurological changes. High
amplitude motor unit potential (a) and reduced interference pattern
(b) in right tibialis anterior muscle are observed.
Figure 3 Gene analysis of the lamin A/C gene (LMNA). Sequencing
of LMNA in our patient shows a heterozygous nonsense mutation
(Q353X) in exon 6 (a). Structure of lamin A and the positions of
mutations in various laminopathies are shown (b). For spinal muscular
atrophy (SMA) phenotype, two of three mutations are located in the
rod domain ([6] and this report). Diamonds indicate the mutations
positions of laminopathies. The rod domain of lamin A is a hot spot
for neuromuscular and cardiac diseases such as Charcot-Marie-Tooth
disease type 2B1 (CMT2B1), dilated cardiomyopathy (DCM),
Emery-Dreifuss muscular dystrophy (EDMD) and limb-girdle
muscular dystrophy (LGMD).
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T) in exon 6 of LMNA was detected (Figure 3a). Exon 6
encodes the rod domain of lamin A and lamin C, which
results in truncated lamin A protein lacking tail domain
including nuclear localization signal (NLS) site (Figure 3b).
The genetic analysis was limited to the proband, as we
could not get a permission from other family members.
The molecular mechanisms of autosomal dominant
SMA are largely unknown. However, Rudnik-Schöneborn
et al. [6] reported adult-onset autosomal dominant prox-
imal SMA phenotype with LMNA mutations in two
families; one family with a novel nonsense mutation
Q493X (c.1477C > T) and the other with missense muta-
tion R377H (c.1130G > T) previously described in Emery-
Dreifuss muscular dystrophy and limb-girdle muscular
dystrophy 1B [7]. Their report indicates that LMNA muta-
tions can mimic SMA and some patients have cardiac
diseases such as atrioventricular block and DCM. The pa-
tients in the two families had onset of gait disturbance
from early adulthood to maturity, with cardiac diseases
diagnosed at the same time or several decades later. In
one family, two of five cousins died from heart attack in
their 40’s-50’s.
Our case is the second report of SMA phenotype with
LMNA mutation. The patient showed muscle weakness
of lower limbs since early childhood, and had cardiac
diseases including atrial fibrillation, atrioventricular
block and cardiac dysfunction in maturity. Amyotrophy
was severe in proximal lower limbs and the trunk. This dis-
tribution of amyotrophy and findings of nerve conduction
study are consistent with proximal SMA phenotype. Theirclinical presentations were similar to previous cases family
especially in cardiopathy, however, the gait disturbance
were shown in different age. He had a novel nonsense
mutation p.Q353X (c.1057C >T) in exon 6 of LMNA
(Figure 3). In general, nonsense mutation in coding exon
results in a significant molecular functional defect even
with heterogeneity. The patient’s uncle (I-4, Figure 1)
showed no muscular weakness, but died suddenly in his
20’s. According to a meta-analysis of carriers of LMNA mu-
tations, sudden death was reported in 46% in both patients
with cardiac diseases and those with neuromuscular dis-
eases [8]. Electrocardiographic findings indicated cardiac
dysrhythmias in 92% of the patients after the age of 30 years,
while heart failure was reported in 64% after the age of
50 years. Furthermore, 28% of carriers of LMNA mutations
were implanted a pacemaker [8].
LMNA spans 12 exons and is located on chromosome
1q21-22. It encodes lamin A and lamin C via alternative
splicing. These lamins belong to the family of type
V intermediate filaments. The protein consists of an
N-terminal head domain, a central α-helical coiled coil
rod domain, and a C-terminal tail domain (Figure 3b)
[9]. Lamins are expressed exclusively in the nucleus of
differentiated cells, and are the major constituents of
the nuclear lamina and distributed in the nucleoplasm
forming a part of the skeleton-type structure. Lamins
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for regulating gene expression.
LMNA mutations have been associated with several
genetic disorders with different phenotypes and heredi-
tary modes. These disorders are called laminopathies,
and they include autosomal dominant Emery-Dreifuss
muscular dystrophy (EMDM), autosomal repressive
EMDM, Limb-girdle muscular dystrophy 1B (LGMD1B),
Dilated cardiomyopathy with conduction defects (CMD1A),
and CMT type 2B1 (CMT2B1). Laminopathies involving
the muscular system and the peripheral nervous system
both of which have mutations mainly at the N-terminal
side of the NLS (Figure 3b). These diseases are suspected
to result from abnormalities of the nuclear laminar struc-
ture. On the other hand, abnormality in genes encoding
lamin-associated proteins such as emerin also caused
EMDM [10], and the pathogenic mechanisms of lamino-
pathies are not clarified. Several phenotypes of laminopa-
thies were reported within the same family [10], and the
interactions with other laminar factors might make part of
the differences.
Distal hereditary motor neuropathies (dHMN), also re-
ferred to as distal SMA, manifest motor-dominant axonal
neuropathy. This group shares several gene mutations
with CMT2 [11,12]. Nevertheless there is no pathological
evidence to differentiate whether our case is proximal
SMA or dHMN, although electrophysiological findings
and the distribution of amyotrophy suggest proximal
SMA phenotype.
Two missense mutations of LMNA; E33D and R298C,
have been reported in CMT2B1 [13,14]. They are associ-
ated with abolished deep tendon reflex and amyotrophy
mainly affecting lower limbs. A combined phenotype
with cardiac complications such as arrhythmia and car-
diomyopathy is possible [13]. Interestingly, some cases
of CMT2B1 due to LMNA mutations show amyotrophy
in proximal limbs [13]. In these cases, degeneration of
neurons in the anterior horn of spinal cord is suspected.
The mechanisms underlying neuropathy and neuronopa-
thy of lower motor neurons may be different.
Conclusions
We report a novel LMNA mutation in a patient with
juvenile-onset SMA-like gait disturbance, combined with
cardiac diseases including atrioventricular block and car-
diac hypofunction with family history of sudden death.
The previous report indicating the nonsense and mis-
sense LMNA mutation can induce SMA phenotype with
cardiomyopathy [6] ensures our similar phenotype case
with novel nonsense LMNA mutation is worth reporting
even though genotype-phenotype cosegregation could
not be demonstrated due to lack of family samples. In
cases of SMA clinical presentation/phenotype without
SMN1 deletion, careful cardiac work-up should beconducted and LMNA gene analysis should be consid-
ered especially when the family history is compatible
with a neuromuscular disease and/or an unexplained
cardiopathy and/or when sudden death are present.
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